Los Angeles, California — January 20, 2026 — Leads & Copy — Kairos Pharma Ltd. (NYSE American: KAPA) will participate in the DealFlow Discovery Conference, scheduled for Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ.
Kairos Pharma Chief Scientific Officer Neil Bhowmick will present at the conference and be available for one-on-one investor meetings during the event.
Investors interested in meeting with the Kairos Pharma management team can request an investor pass to attend the conference at dealflowdiscoveryconference.com. There is no cost to attend.
Kairos Pharma Ltd., based in Los Angeles, California, focuses on oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy.
ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing unmet medical needs.
As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
Contact:
Neil Bhowmick
Chief Scientific Officer
Source: Kairos Pharma Ltd.
